Trade Secrets

Why F1 teams need to do more with IP

Many are looking for opportunities to expand their technology into other areas of the auto sector, but to do so effectively a greater focus on patents is essential

Why F1 teams need to do more with IP
Surprise change to FDA Purple Book creates risks and opportunities for biosimilar producers
7 Jan 2021

Surprise change to FDA Purple Book creates risks and opportunities for biosimilar producers

A US patent transparency amendment has mixed implications for the strategies pursued by biologics copycat producers

All the China IP stories you missed over the holidays
4 Jan 2021

All the China IP stories you missed over the holidays

Wuhan injunction drama was far from the only big IP news to come out of China over the festive period

Latest

View all
22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

12 Dec 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models Read more

4 Dec 2020

3M’s diversity pioneer on why data and collaboration are key to broadening the innovation pool

After seeing her work recognised by the IPO, the company's assistant chief IP counsel Sandra Nowak spoke with IAM on why some parts of the market are still playing catch-up Read more

24 Nov 2020

Criminal trade secrets law in China targets foreigners with extra penalties

Likely a response to recent US prosecutions of Chinese nationals, the measures mean foreign companies in China should tread with caution Read more

News

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

28 Oct 2020

Help us to identify the world's leading IP strategists

The research process for the IAM Strategy 300 2021 is now underway and we are inviting nominations as we decide who should be included Read more

24 Oct 2020

To educate lawyers who change the world, we cannot let this crisis go to waste

As the covid-19 pandemic continues to upend education in the US and beyond, there is an opportunity to create a new normal in how IP is taught, says Megan Carpenter, Dean of the Franklin Pierce School of Law Read more

Analysis

View all
19 Nov 2020

“This is becoming an investible space,” says Aon IP head as financial giant rolls out M&A-focused product

Sell-side tool is designed to help the dealmaking community better understand the value of patents and other intangible assets Read more

17 Nov 2020

Data is the new frontier in healthcare IP licensing, says award-winning TTO

IAM speaks to the tech transfer office of Oregon Health & Science University about the keys to success in university-industry deal-making Read more

11 Nov 2020

How a Korean IP dispute could become political fodder in crucial Georgia Senate run-off

With the future of a planned battery factory on the line, President Trump may face ITC veto choice in midst of vote that could decide which party controls Congress Read more

10 Nov 2020

Big Tech is on notice in China, too

New rules for the internet sector call out long-standing business practices and look at data, technology and IP ownership Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more